Kiyatec Announces New Clinical Evidence in High Grade Glioma Accepted for Presentation at the Annual Meeting of ASCO 2022
GREENVILLE, S.C.--June 2, 2022--(BUSINESS WIRE)--Kiyatec, a leader in functional precision oncology, announced new clinical evidence of its proprietary ex vivo 3D cell culture technology use in high-grade glioma will be…